Compare Stocks: PHIO, INMB, TIL, and TCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INMB INmune Bio	$2.09 +9.2%	$1.63	$1.09 ▼ $2.61	$55.43M	0.97	509,155 shs	952,600 shs
PHIO Phio Pharmaceuticals	$1.04 -1.9%	$1.04	$0.81 ▼ $4.19	$12.08M	0.82	1.53 million shs	86,066 shs
TCRX TScan Therapeutics	$0.80 +4.3%	$0.92	$0.72 ▼ $2.57	$52.03M	1.06	635,119 shs	325,230 shs
TIL Instil Bio	$7.41 +1.8%	$7.59	$5.67 ▼ $33.83	$50.25M	1.94	11,236 shs	11,555 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INMB INmune Bio	0.00%	+19.14%	+16.48%	+45.80%	-24.46%
PHIO Phio Pharmaceuticals	0.00%	+1.46%	0.00%	-2.80%	-55.36%
TCRX TScan Therapeutics	0.00%	+7.16%	-24.89%	-36.81%	-53.98%
TIL Instil Bio	0.00%	+4.07%	-3.26%	-9.19%	-71.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INMB INmune Bio	$2.09 +9.2%	$1.63	$1.09 ▼ $2.61	$55.43M	0.97	509,155 shs	952,600 shs
PHIO Phio Pharmaceuticals	$1.04 -1.9%	$1.04	$0.81 ▼ $4.19	$12.08M	0.82	1.53 million shs	86,066 shs
TCRX TScan Therapeutics	$0.80 +4.3%	$0.92	$0.72 ▼ $2.57	$52.03M	1.06	635,119 shs	325,230 shs
TIL Instil Bio	$7.41 +1.8%	$7.59	$5.67 ▼ $33.83	$50.25M	1.94	11,236 shs	11,555 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INMB INmune Bio	0.00%	+19.14%	+16.48%	+45.80%	-24.46%
PHIO Phio Pharmaceuticals	0.00%	+1.46%	0.00%	-2.80%	-55.36%
TCRX TScan Therapeutics	0.00%	+7.16%	-24.89%	-36.81%	-53.98%
TIL Instil Bio	0.00%	+4.07%	-3.26%	-9.19%	-71.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A
PHIO Phio Pharmaceuticals	2.00	Hold	$14.00	1,246.15% Upside
TCRX TScan Therapeutics	2.33	Hold	$6.00	653.58% Upside
TIL Instil Bio	1.67	Reduce	$66.00	790.69% Upside

Current Analyst Ratings Breakdown

Latest PHIO, INMB, TIL, and TCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	PHIO Phio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
6/23/2026	TCRX TScan Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.00
6/11/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INMB INmune Bio	N/A	N/A	N/A	N/A	$0.88 per share	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$1.87 per share	N/A
TCRX TScan Therapeutics	$10.32M	5.04	N/A	N/A	$2.16 per share	0.37
TIL Instil Bio	N/A	N/A	N/A	N/A	$16.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INMB INmune Bio	-$45.93M	-$0.67	N/A	N/A	N/A	N/A	-80.62%	-60.36%	N/A
PHIO Phio Pharmaceuticals	-$8.70M	-$1.29	N/A	N/A	N/A	N/A	-77.34%	-70.87%	8/13/2026 (Estimated)
TCRX TScan Therapeutics	-$129.77M	-$0.96	N/A	N/A	N/A	-1,360.61%	-91.94%	-50.15%	8/11/2026 (Estimated)
TIL Instil Bio	-$71.37M	-$7.08	N/A	N/A	N/A	N/A	-39.76%	-22.38%	8/10/2026 (Estimated)

Latest PHIO, INMB, TIL, and TCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TCRX TScan Therapeutics	-$0.29	N/A	N/A	N/A	$1.88 million	N/A
8/10/2026	N/A	TIL Instil Bio	-$0.35	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	-$0.05	+$0.1567	-$0.05	$1.16 million	N/A
8/6/2026	Q2 2026	PHIO Phio Pharmaceuticals	-$0.36	-$0.36	N/A	-$0.36	N/A	N/A
5/15/2026	Q1 2026	TIL Instil Bio	-$0.62	-$0.62	N/A	-$0.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INMB INmune Bio	N/A	4.24	4.24
PHIO Phio Pharmaceuticals	N/A	18.32	18.32
TCRX TScan Therapeutics	0.34	6.65	6.65
TIL Instil Bio	0.77	39.87	39.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INMB INmune Bio	12.72%
PHIO Phio Pharmaceuticals	57.31%
TCRX TScan Therapeutics	82.83%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
INMB INmune Bio	21.40%
PHIO Phio Pharmaceuticals	0.89%
TCRX TScan Therapeutics	6.25%
TIL Instil Bio	47.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INMB INmune Bio	10	26.59 million	20.90 million	Optionable
PHIO Phio Pharmaceuticals	10	11.62 million	11.51 million	Not Optionable
TCRX TScan Therapeutics	100	65.35 million	61.27 million	Not Optionable
TIL Instil Bio	410	6.78 million	3.59 million	No Data

PHIO, INMB, TIL, and TCRX Headlines

Recent News About These Companies

Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

July 16, 2026 | seekingalpha.com

Instil Bio Shareholders Back Directors and Auditor at Meeting

June 11, 2026 | tipranks.com

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 15, 2026 | globenewswire.com

Instil Bio (TIL) Price Target Increased by 24.53% to 67.32

April 9, 2026 | msn.com

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 12, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 3, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 29, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,

January 27, 2026 | bakersfield.comB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 22, 2026 | prnewswire.com

TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky

January 20, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 20, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 15, 2026 | prnewswire.com

Instil Bio (TIL) Price Target Decreased by 45.17% to 53.55

January 14, 2026 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 13, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 8, 2026 | prnewswire.com

HC Wainwright & Co. downgrades Instil Bio (TIL)

January 8, 2026 | msn.com

Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug

January 7, 2026 | biopharmadive.comB

Instil Bio shares slide on discontinuation of lead clinical programs

January 6, 2026 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHIO, INMB, TIL, and TCRX Company Descriptions

INmune Bio NASDAQ:INMB

$2.08 +0.18 (+9.16%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.05 -0.04 (-1.68%)

As of 08/7/2026 07:34 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Phio Pharmaceuticals NASDAQ:PHIO

$1.04 -0.02 (-1.89%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.05 +0.01 (+1.35%)

As of 08/7/2026 07:56 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

TScan Therapeutics NASDAQ:TCRX

$0.80 +0.03 (+4.32%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$0.79 0.00 (-0.28%)

As of 08/7/2026 07:34 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Instil Bio NASDAQ:TIL

$7.41 +0.13 (+1.79%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$7.24 -0.17 (-2.28%)

As of 08/7/2026 07:56 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHIO, INMB, TIL, and TCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHIO, INMB, TIL, and TCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHIO, INMB, TIL, and TCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHIO, INMB, TIL, and TCRX Company Descriptions

INmune Bio NASDAQ:INMB

Phio Pharmaceuticals NASDAQ:PHIO

TScan Therapeutics NASDAQ:TCRX

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHIO, INMB, TIL, and TCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHIO, INMB, TIL, and TCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHIO, INMB, TIL, and TCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHIO, INMB, TIL, and TCRX Company Descriptions

INmune Bio NASDAQ:INMB

Phio Pharmaceuticals NASDAQ:PHIO

TScan Therapeutics NASDAQ:TCRX

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools